Media headlines about Acorda Therapeutics (NASDAQ:ACOR) have trended somewhat positive this week, Accern reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acorda Therapeutics earned a news impact score of 0.20 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.184265856774 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Acorda Therapeutics Inc (ACOR) Given Average Rating of “Hold” by Analysts (americanbankingnews.com)
- Acorda Therapeutics, Inc. (ACOR) has a value of $23.05 per share While Intrexon Corporation (XON) is stand at $19.83 – Stocks Gallery (stocksgallery.com)
- Parkinson’s Disease – Pipeline Review, H1 2017 Market Report; Launched via MarketResearchReports.com (sbwire.com)
- Acorda Therapeutics : to Present at the Cantor Fitzgerald Global Healthcare Conference (4-traders.com)
- Acorda to Present at the Cantor Fitzgerald Global Healthcare Conference – Business Wire (press release) (businesswire.com)
Several brokerages have recently issued reports on ACOR. BidaskClub upgraded Acorda Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, July 7th. Cowen and Company reiterated an “outperform” rating and set a $35.00 price objective on shares of Acorda Therapeutics in a research report on Wednesday, June 7th. Janney Montgomery Scott reiterated a “hold” rating and set a $18.00 price objective on shares of Acorda Therapeutics in a research report on Wednesday, August 30th. J P Morgan Chase & Co set a $24.00 price objective on Acorda Therapeutics and gave the stock a “hold” rating in a research report on Tuesday, June 6th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $26.00 price objective (down from $30.00) on shares of Acorda Therapeutics in a research report on Thursday, August 31st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Acorda Therapeutics currently has an average rating of “Hold” and a consensus price target of $24.36.
Acorda Therapeutics (NASDAQ ACOR) traded down 0.65% during midday trading on Friday, reaching $22.95. The company’s stock had a trading volume of 1,467,154 shares. The stock’s market capitalization is $1.07 billion. Acorda Therapeutics has a 52-week low of $13.60 and a 52-week high of $33.00. The firm has a 50-day moving average price of $22.06 and a 200 day moving average price of $20.23.
Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.16. Acorda Therapeutics had a negative net margin of 5.88% and a negative return on equity of 4.81%. The business had revenue of $139.40 million for the quarter, compared to analysts’ expectations of $139.81 million. During the same period in the prior year, the firm earned $0.07 earnings per share. Acorda Therapeutics’s revenue was up 9.3% compared to the same quarter last year. Equities research analysts predict that Acorda Therapeutics will post $1.71 EPS for the current fiscal year.
In other news, Director Lorin Randall sold 10,000 shares of the stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $21.66, for a total transaction of $216,600.00. Following the sale, the director now directly owns 10,000 shares of the company’s stock, valued at $216,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Scopia Capital Management Lp purchased 766,201 shares of the firm’s stock in a transaction dated Tuesday, August 29th. The shares were bought at an average cost of $19.23 per share, for a total transaction of $14,734,045.23. The disclosure for this purchase can be found here. 7.90% of the stock is owned by corporate insiders.
WARNING: This article was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://sportsperspectives.com/2017/09/17/acorda-therapeutics-acor-given-daily-news-sentiment-score-of-0-20.html.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.